



PRESS RELEASE APRIL 21, 2010

## **MOBERG DERMA AND MEDICAL FUTURES INC SIGNS COMMERCIAL AGREEMENT FOR NAIL PRODUCT IN CANADA**

Moberg Derma AB, Sweden and Medical Futures Inc, Canada ("MFI"), today announced a commercial license agreement. The license covers distribution in Canada for Moberg Derma's novel topical nail product – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while MFI will be responsible for promotion in the Canadian market. Financial terms include payments for product supply and milestones.

"Our joint goal is to build a significant franchise in the Canadian market for nail disease treatments. We are impressed with MFI's approach and momentum and are excited about the prospects of our collaboration", says Moberg Derma's President and CEO, Peter Wolpert.

Paul Johns, VP Sales and Marketing of Medical Futures Inc., says: "I am very pleased that we secured a collaboration with Moberg Derma, one of few companies bringing innovation in Dermatology. We identified Moberg's new nail product as the most promising novel topical treatment alternative for nail fungus. This is a large disease area previously lacking good products. This latest addition to our portfolio has the potential to become an important growth driver for MFI"

### **About the product and nail fungus**

Moberg's topical nail product is prescription free and has the potential to become first-line treatment for common nail disorders. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. The product has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

### **Contact Moberg Derma**

Peter Wolpert, President and CEO  
Telephone: +46 8 - 522 307 00  
Mobile: +46 70 - 735 71 35  
E-mail: [peter.wolpert@mobergderma.se](mailto:peter.wolpert@mobergderma.se)

### **Contact Medical Futures**

Matthew Kostanecki, Business Development and Marketing Coordinator  
Telephone: 1 905 731-0294 x151  
Email: [matthew@medfutures.com](mailto:matthew@medfutures.com)

### **About Moberg Derma**

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights. The company began operations at the Karolinska Institute in 2006. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: [www.mobergderma.se](http://www.mobergderma.se)

### **About Medical Futures**

Medical Futures Inc. Richmond Hill, Canada, is a niche pharmaceutical company that distributes both pharmaceutical and natural therapeutic products into the North American marketplace. Founded in 2000, this privately held company is dedicated to advancing the quality of life for all Canadians. For more information about Medical Futures, go to [www.medfutures.com](http://www.medfutures.com).